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Synaptic plasticity simply put, is the activity‑dependent modification of the strength or efficacy of synaptic transmission in the network of 
synapses in the brain. The role of synaptic plasticity in disease is an active area of research. Changes in plasticity translate to the release 
of neurotransmitters at the synapse and subsequently, the way humans see the world. It is known that neuropsychiatric disorders 
such as depression, posttraumatic stress disorder (PTSD), and Alzheimer’s disease (AD) are related to pathological changes in dynamic 
processes in synapses, dialogue between neurons, and finally, changes in overall plasticity. To find a cure for these plasticity related 
diseases, it is imperative that we understand the precise mechanisms that perturb the homeostatic balance leading to the disease state.
The aim of this review is to present what is currently known about DSCAM (Down Syndrome Cell Adhesion Molecule) a protein that is 
directly connected to pathological changes in synaptic plasticity. The review will present information on DSCAM and how it is connected 
to glutamate (Glu) and γ‑Aminobutyric acid (GABA) neurotransmission pathways. Finally, the review throws some light on the possible 
involvement of DSCAM in a spectrum of psychiatric disorders apart from Down syndrome (DS).
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INTRODUCTION
In 1949, Donald Hebb postulated that strong inter‑
actions existed between communicating synapses, a re‑
mark often presented as: “Fire together, wire together” 
(Hebb 1949). Synaptic plasticity is a language of neuro‑
nal communication and depends on timing, the strength 
of pre‑ and postsynaptic dialogue, and the structure of 
dendritic spines (Cramer and Galdzicki 2012, Dan and 
Poo 2006). The process of synapse strengthening in‑
volves several factors, including the formation of new 
dendritic spines, modification of existing synapses 
through receptor variation, silent synapse activation, 
changes in the size or shape of the synapse, and chang‑
es in the timing and levels of neurotransmitter release 
(Kossut 2007). The number of spines, their localization, 
and the shape of individual spines are important factors 
in this process (Alves‑Sampaio et al. 2010). Any disrup‑
tion to this communication path results in the reduction 
of potential sites for the occurrence of plasticity (Cram‑
er and Galdzicki 2012). 
Cell Adhesion Molecules (CAMs) are known partici‑
pants in the process of forming synaptic connections, 
together with other cell surface recognition molecules 
they take part in the processes of homophilic and het‑
erophilic bindings, fasciculation, and defasciculation 
(Hattori et al. 2008). Down Syndrome Cell Adhesion 
Molecule (DSCAM) is an important factor in the process 
of synapse strengthening and the timing of synaptic 
dialogue transmission (Li et al. 2009). Often, synapse 
dialogue is discussed in terms of long‑term potentia‑
tion (LTP) and/or long‑term depression (LTD). LTP is 
a long‑lasting enhancement of synaptic efficacy and is 
a predictor of synaptic plasticity, as well as a learning 
and memory sensor. Both processes are strictly linked 
to glutamate (Glu) activation.
Pathological changes in the dynamic processes that 
occur at synapses coupled with neurotransmission shifts 
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are characteristic features of many neuropsychiatric 
diseases. In addition, characteristic changes in DSCAM 
levels are observed. Although DSCAM plays unquestion‑
able roles in the different steps of neural circuit forma‑
tion (Alves‑Sampaio et al. 2010), dendritic tree forma‑
tion and synaptogenesis (Hortsch and Umemori 2009, 
Jia et al. 2011, Pérez‑Núñez et al. 2016, Schmucker and 
Chen 2009, Zhu et al. 2006), the more interesting ques‑
tions to ask are: 1) How does this knowledge help us in 
understanding synaptic plasticity and its role in the 
pathophysiology of neuropsychiatric disorders? 2) Is the 
DSCAM protein/gene only an “observer” of the changes 
in equilibrium, or an active player? To accurately answer 
these questions, we need to have a precise view of all 
changes that take place in Down syndrome (DS) – the 
best model of disturbed plasticity and learning poten‑
tial, with a characteristic decrease in dendritic branch‑
ing and spine density in the hippocampus and cortex in 
parallel to overexpressed DSCAM (Alves‑Sampaio et al. 
2010, Ferrer and Gullotta 1990, Sterne et al. 2015).
Function
Cadherins Integrins Selectins IgSF
– surface glycoproteins
– calcium dependent
– cell‑cell adhesion
– tissue patterning
– cancer
– heterodimers
–  transmembrane linkers: 
extracellular matrix and actin 
cytoskeleton
– fi rst step of adhesion
–  the attachment of leukocytes 
to the wall
L‑selectins are expressed on 
circulating leukocytes
P‑selectins – on endothelial cells 
and granules of platelets
E‑selectins – induced by IL‑1, LPS, 
TNF on vascular endothelial cells
–  cell surface receptors 
and cell adhesions
DSCAM
NCAMs
ICAMs
VCAMs
PECAM‑1
ESAM
–  function mainly in 
the immune system
–  cell‑cell reorganisation
(Kourtidis et al. 2017, Bajnok et al. 2017, Springer 1994, Alberts et al. 2002, Harpaz and Chothia 1994, Giancotti and Ruoslathi 1999, Wong et al. 2012).
Fig. 1. Classifi cation and function of Cell Adhesion Molecules (CAMs).
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DSCAM – a Down Syndrome Cell Adhesion Molecule
The DSCAM gene is located on human chromosome 
21 (21q22.2–q22.3), which is strictly associated with DS 
(Edelman and Crossin 1991, Head et al. 2007, Yamakawa 
et al. 1998). A second DSCAM gene is located on chro‑
mosome band 11g23 (DSCAML1), where it is associated 
with Tourette’s syndrome (Agarwala et al. 2001). DSCAM 
belongs to the immunoglobulin superfamily of cell ad‑
hesion molecules (Ig‑CAMs) (Yamakawa et al. 1998) and 
is a cell surface transmembrane receptor (Hortsch and 
Umemori 2009). Cell adhesion molecules (CAMs) medi‑
ate cell‑to‑cell and/or cell‑to‑extracellular matrix in‑
teractions and are predominantly classified as integrins, 
selectins, cadhedrins and the immunoglobulin super‑
family (IgSF) (Wong et al. 2012). Besides DSCAM, oth‑
er IgSF members include: NCAM (Neural Cell Adhesion 
Molecule, CD56), ICAM (Intracellular Adhesion Molecule, 
CD54), VCAM (Vascular Cell Adhesion Protein 1) and PE‑
CAM‑1 (Platelet Endothelial Cell Adhesion Molecule, 
CD31) (Wong et al. 2012), (see Fig. 1 for classification and 
function of CAMs). 
DSCAM is one of the largest IgSF proteins (220kDa); 
it is composed of an N‑terminal signal peptide, 10 im‑
munoglobulins (Igs) and 6 fibronectin type III (FNIII) 
domains, a transmembrane domain (TM) and a cyto‑
plasmic tail (Hortsch and Umemori 2009, Jin et al. 2013, 
Yamakawa et al. 1998). The tenth Ig domain is separat‑
ed by the fourth and fifth FNIII domains. The domain 
structure composition of DSCAM is truly unique and dif‑
ferentiates it from other members of the IgSF (Hortsch 
and Umemori 2009). A single membrane‑spanning do‑
main links the extracellular domain with the cytoplas‑
mic fragment of DSCAM (Hortsch and Umemori 2009). 
The cytoplasmic fragment of DSCAM is composed of 
300‑400 amino acids with high level of tyrosines serv‑
ing as a binding site for the SH2 domain of dedicator 
of cytokinesis (Dock) proteins or the postsynaptic den‑
sity protein (PDZ) domain binding‑site (Hortsch and 
Umemori 2009) (Fig. 2). 
DSCAM transcripts are subject to alternative splicing 
and therefore can generate various tissue‑specific pro‑
tein isoforms (Hortsch and Umemori 2009). DSCAM was 
found in the neurons of the central nervous system (CNS) 
and peripheral nervous system (PNS) during the mouse 
developmental period. Precisely, DSCAM expression was 
detected in tissues such as the liver, lungs, limb, and 
buds only during the developmental period (Agarwala et 
al. 2001). It is equally expressed in the cortex, olfactory 
bulb, dentate gyrus, hippocampus (CA1, CA3), thalamus, 
and cerebellum of the adult mouse brain (Agarwala et 
al. 2001). More precisely, DSCAM receptors were found 
on the dendrites and axons of neurons (Hortsch and 
Umemori 2009). DSCAML1 shows differential expression 
patterns compared to DSCAM during development and 
in adult mice, e.g. DSCAM shows strongest expression in 
the pyramidal neurons of the cortex layers 3 and 5 (Bar‑
low et al. 2002). 
Both forms of DSCAM are expressed in the hippo‑
campus (with higher expression in the dentate gyrus 
and Ammon’s horn) and in the olfactory bulb (Barlow et 
al. 2002). Apart from its expression in the brain of adult 
mice, DSCAML1 is also expressed in tissues such as the 
heart, spleen, lungs, kidneys, and testis (Barlow et al. 
2001, Barlow et al. 2002). In humans, both DSCAM and 
DSCAML1 are expressed in the hippocampus, amygdala, 
thalamus, caudate nucleus, and corpus callosum (Bar‑
low et al. 2002, Yamakawa et al. 1998). Overexpression 
of DSCAM has also been documented in the brains of hu‑
man patients with DS (Bahn et al. 2002, Head et al. 2007, 
Sterne et al. 2015). Saito et al. (2000) reported the pres‑
ence of DSCAM in the cerebellar white matter of control 
and DS patients and suggested DSCAM may play a role in 
regulating myelination.
Fig. 2. Structure of DSCAM.
DSCAM is a  transmembrane receptor, Ig‑CAM protein. The Structure of 
DSCAM is composed of 10 Ig domains, and 6 fi bronectin type III (FN  III) 
domains, tandemly arranged. The DSCAM family consists of 2000 
amino acids, with an average molecular weight of 220kDa. Extracellular 
domain units are connected with the cytoplasmic region of DSCAM by 
a  membrane‑spanning domain. DSCAM cytodomains contain various 
tyrosines, which are binding sites for i.e. Src Homology 2 (SH2) domain 
(Docks) and PDZ domain‑binding (Hortsch and Umemori Eds 2009).
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Although DSCAM has been shown to be essential in 
the organization of the nervous system, dendritic tree 
formation and synaptogenesis (Hortsch and Umemori 
2009, Jia et al. 2011, Pérez‑Núñez et al. 2016, Schmucker 
and Chen 2009, Zhu et al. 2006), some controversy still 
exists in the field concerning its role in the CNS. The 
paragraphs that follow will attempt to shed more light 
on its role in the CNS based on its role in DS and non‑DS 
conditions. Furthermore, its connection with major neu‑
rotransmission pathways will be discussed.
DSCAM in DS and other conditions
Down syndrome
DS is an outcome of trisomy of human chromo‑
some 21, the most common reason of genetic mental 
retardation (Alves‑Sampaio et al. 2010, Antonarakis et 
al. 2004). Although a considerable amount of individ‑
ual variability exists in persons with DS, they exhibit 
a characteristic intellectual disability, with decreased 
IQ score and speech problems that get worse during ag‑
ing (Hickey et al. 2012, Weijerman and Winter 2010). 
Morphologically decreased brain size, aberrant gyrifi‑
cation, and disturbed neurogenesis are also observed 
(Lockstone et al. 2007, Mrak and Griffin 2004). As an 
outcome of reduced brain size, reduced volumes of ce‑
rebral gray and white matter are observed (Pinter et al. 
2001). At the same time, larger subcortical and parietal 
gray matter and temporal white matter are present, 
which according to Pinter et al. (2001) may be the cause 
of verbal memory deficits, and changes in short‑term 
visuospatial memory. Cognitive deficits in DS persons 
comprise of long‑term memory changes and difficulty 
in the assimilation of new skills (Pennington et al. 2003, 
Yu et al. 2010). 
In DS persons, dendritic branching and spine densi‑
ty are diminished both in the hippocampus and cortex 
(Alves‑Sampaio et al. 2010), with changes in the mor‑
phology and volume of these structures. Ferrer and 
Gullotta (1990) reported a 15% decrease in DS hippo‑
campal spines. Similar morphological changes have also 
been reported in mouse models of DS (Ts65Dn and Ts1Cje 
mice). Both models show similar phenotypes and char‑
acteristic morphological changes, although obtained by 
different chromosomal manipulations. Because this is 
not a major focus of this study, readers can review Olson 
et al. (2004) or Belichenko et al. (2015) for detailed infor‑
mation on both models. 
Decreased spine densities and increased spine vol‑
umes in the neocortex and hippocampus were found in 
the Ts65Dn mouse model of DS (Belichenko et al. 2004, 
Siarey et al. 2006). 
Furthermore, specific presynaptic bouton enlarge‑
ments and the presence of a great number of vacu‑
oles and multivesicular bodies in spines were found 
in Ts65Dn mice (Belichenko et al. 2004). Characteristic 
changes in hippocampus inhibitory synapse position 
from shafts onto the necks of dendrites were also doc‑
umented in these mice (Belichenko et al. 2004, Cramer 
and Galdzicki 2012). Deficits in cognitive tests were 
found to be linked to reduced hippocampal volumes 
(Cramer and Galdzicki 2012). Furthermore, exagger‑
ation of inhibition in the trisomic hippocampus was 
documented (Ts65Dn) (Cramer and Galdzicki 2012). In 
a parallel study, Alves‑Sampaio et al. (2010) showed 
that DSCAM plays a functional role in dendritogene‑
sis and synaptic plasticity. Using a plasmid encoding 
DSCAM‑IRES‑GFP, the authors showed significantly 
reduced neurites crossing, using Sholl morphometric 
analysis, and reduced total dendrite length in hip‑
pocampal DSCAM‑overexpressing neurons. Further‑
more, the hippocampus of Ts1Cje mice had increased 
levels of DSCAM mRNA and protein (Alves‑Sampaio et 
al. 2010). 
Mood related disorders
Neuronal atrophy and cognitive deficits are 
also known characteristics of depression and other 
stress‑mediated disorders (Yu et al. 2011). Stress‑me‑
diated changes in neuroplasticity in the dentate gy‑
rus have been proposed to play significant roles in the 
pathophysiology of depression, despite some critical 
reports (Liu et al. 2017). Reductions in dendrite arbor‑
ization and spine density have been reported in the 
cortex of postmortem brains of depressed patients 
(Banasr et al. 2011, Rajkowska and Miguel‑Hidalgo 
2007). Early life stress is an accepted factor in pro‑
ducing neuropsychiatric changes during adolescence, 
as well as being linked to reduced dendritic length, 
branching, and spine density in the limbic structures 
and prefrontal cortex (Brenhouse and Andersen 2011, 
Lupien et al. 2009). Loss of spines and withdrawal of 
dendrites of pyramidal neurons of the prefrontal cor‑
tex in rodents is common in chronic stress (Banasr et 
al. 2011, Radley et al. 2004). Importantly, antidepres‑
sant drugs are effective as neuroplasticity enhancers 
(Banasr et al. 2011, Eyre and Baune 2012). Further‑
more, Amano et al. (2008) found an association be‑
tween increased DSCAM expression and bipolar disor‑
der in a gene screen of patients with bipolar disorder 
(manic‑depressive disorder). Postmortem examina‑
tion of brains from bipolar subjects carrying the G al‑
lele of DC141 SNP, showed elevated levels of DSCAM 
(Amano et al. 2008). 
214 K. Stachowicz Acta Neurobiol Exp 2018, 78: 210–219
Posttraumatic stress disorder (PTSD)
Results obtained in the screen of genes in the glu‑
cocorticoid receptor (GR) pathway and genes of the 
neural stress response in PTSD patients (male veter‑
ans), found low levels of expression of DSCAM in the 
test group compared to controls (Logue et al. 2015). In‑
terestingly, a parallel decrease in BDNF expression was 
also observed in these patients (Logue et al. 2015). It is 
very interesting to note that DSCAM is downregulated 
in PTSD, where individuals may not forget the traumat‑
ic events in their lives. 
Alzheimer’s disease (AD)
Mental retardation presents the direct opposite of 
PTSD with an upregulated level of DSCAM. Dementia is 
not uncommon after 20‑years or later in the life of DS 
persons (Myers and Pueschel 1991). Some DS persons de‑
velop AD with dementia later in life; while some have 
evidence of AD neuropathology but may not develop de‑
mentia (Head et al. 2007). Chromosome 21 links DS with 
familial AD (St George‑Hyslop et al. 1987). DS is a result 
of trisomy 21, with triplication of other genes, e.g. the 
APP gene, leading to increased Amyloid‑β (Aβ) levels 
in the brain, which is a characteristic neuropatholo‑
gy of AD (Doran et al. 2017). In familial early‑onset AD, 
a duplication of the APP genomic locus may occur that 
is known as partial trisomy of chromosome 21 (PT21), 
with absence of the clinical symptoms characteristic of 
DS (Doran et al., 2017, Sleegers et al. 2006). 
Doran et al. (2017) suggests that APP is critical to the 
pathogenesis of AD in DS, as DS patients normosomic for 
APP showed very slow cognitive loss. Imaging studies 
using PET suggest compensatory increases in metabolic 
Table I. Main changes observed in Down syndrome, Alzheimer disease, depression and PTSD – comparative study.
Down 
syndrome Alzheimer disease Depression PTSD References
A
DSCAM ↑ protein/human/
brain
↑ APP transgenic 
mice/brain/gene/
protein
↑ (bipolar)serum and 
postmortem brain/
human/gene
↓ gene/human/
blood
(Saito et al. 2000,  
Jia et al. 2011,  
Amano et al. 2008, 
Logue et al. 2015)
Spine density/
dendritic branching
↓ spine numbers/
Ts65Dn  
↑ mice/Hp
spine heads/Hp
↓ dendritic spines/
Hp/Cx
↓ rats dendric spine 
 density Hp (CA1,CA3); 
DG
↓ PTSD patients/mice
(type‑dependent)
(Kurt et al. 2004, Chen 
et al. 2012, Dorostkar 
et al. 2015, Norrholm 
and Ouimet 2001, 
Madder 2017,  
Young et al. 2015)
Cortico
‑sterone
↑ Ts65Dn mice large 
group housing
↑ Hp culture ↑ human/serum ↕ PTSD  
↔ patients/mice
(Martίnez‑Cué et al. 
2005, Wuwongse et 
al. 2013, Pariante 
and Lightman 2008, 
Madder 2017,  
Otte et al. 2005)
B
LTP ↓ Hp/Ts65Dn ↓ Hp/APP mice/
human Cx
↓ rats/Hp ↑ biphasic/Hp/Am/
rats
(Siarey et al. 1999, 
Chapman et al. 1999, 
Koch et al. 2012, Liu 
et al. 2017, Akirav and 
Richter‑Levin 1999)
Glu ↔ fetus/Cx ↓ Human/Cx/
HPLC
Reuptake Hp
↑ (bipolar/MDD) 
 Fcx 
↑ Hp/rats
Am/Hp/human
(Whittle et al. 2007, 
Gueli and Taibi 
2013, Zhang et al. 
2016, Li et al. 2011, 
Hashimoto et al. 
2007, Gao et al. 2014, 
Friedman et al. 2014)
GABA ↓ fetus/Cx ↓ Human/Cx/
HPLC
↑ Hp/HPLC/
Astrocytes
↓ (bipolar)serum 
 human 
↑ Hp/rats (Whittle et al. 2007, 
Gueli and Taibi 2013, 
Li et al. 2016,  
Petty et al. 1993,  
Gao et al. 2014)
↑ ↓ increase, decrease, ↕ different results – increase and decrease, ↔ no difference or difficult to assess.
Hp – Hippocampus, Am – Amygdala, Cx – Cortex, DG – Dentate Gyrus, FCx – Frontal Cortex, PTSD – Post Traumatic Stress Disorder, Ts65Dn – mouse Down Syndrome model, 
APP – mouse Alzheimer’s Disease model.
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rate in vulnerable brain regions in DS prior to the de‑
velopment of dementia (Head et al. 2007). In fact, Head 
et al. (2007) found DSCAM localization in cores and pe‑
ripheral fibers linked to senile plaque formation in DS 
with AD. Amyloid precursor protein (APP) transgenic 
mice (a model of AD) showed a significantly higher level 
of DSCAM expression in the cerebral cortex, compared 
with the control wild‑type group (Jia et al. 2011). It was 
speculated that the observed effect was a leading cause 
of learning, memory, sensory perception and voluntary 
movement deficits in APP transgenic mice (Jia et al. 
2011). In the mouse model of AD (APP transgenic mice), 
the DSCAM level was found to progressively increase 
with age (Jia et al. 2011). However, APP and DSCAM asso‑
ciations seen both in DS persons and AD models should 
be considered as more complex than additive effects 
of potentially overexpressed proteins. Since AD mouse 
models show microglial and astrocytic activation, with 
increased levels of cytokines and cyclooxygenase‑2 
(COX‑2) (Birch et al. 2014), while DSCAM represents an 
IgSF member (Wong et al. 2012), implication of the in‑
flammatory response should be considered in that con‑
text. In fact, our data found engagement of COX‑2 in the 
regulation of DSCAM levels in the mouse brain (unpub‑
lished data).
The proportion of DSCAM, corticosterone levels and 
changes in spine density in DS and neuropsychiatric dis‑
orders discussed above are shown in Table IA. Because 
changes in plasticity are strictly linked to fluctuations in 
interactions between neurotransmitters, including tran‑
scriptional and translational changes, the remainder of 
the review will focus on such signaling pathways, with 
particular attention to the involvement of DSCAM. 
Glutamate, GABA and DSCAM expression 
Studies on DSCAM and its interaction with neu‑
rotransmitters are mostly based on animal models. Li 
et al. (2009) suggested that Dscam‑mediated signaling 
was substantially involved in Glu receptor changes. Us‑
ing the Aplysia culture model, Li et al. (2009) document‑
ed Dscam‑mediated trans‑synaptic interactions acting 
through α‑amino‑5‑hydroxy‑3‑methyl‑4‑isoxazole pro‑
pionic acid (AMPA) receptors. For clustering of AMPA re‑
ceptors, during de novo synapse formation, a presynaptic 
input is required. Li et al. (2009) abolished both synap‑
tic transmission and AMPA‑like receptor clustering, by 
blockade of pre‑ and postsynaptic Dscam. At the same 
time NMDA‑like receptor clustering was found to be 
Dscam independent (Li et al. 2009). Dscam not only sta‑
bilizes presynaptic structures at postsynaptic sites but 
is required for precise wiring during synapse formation 
in the learning process (Li et al. 2009). Revitalization of 
Dscam‑mediated signaling by induction of long‑term 
facilitation (LTF) is needed during learning‑related syn‑
apse formation (Li et al. 2009). LTF induced by a series 
of 5‑HT pulses was shown as an increase in NMDA and 
AMPA receptors at the Aplysia sensory‑motor neuron 
synapse, 12 h post factum and was Dscam‑dependent (Li 
et al. 2009). The following processes were Dscam‑depen‑
dent: remodeling of AMPA receptors, stabilization and 
formation of new synaptic connections (Li et al. 2009). 
The influence of NMDA on DSCAM expression 
has been confirmed in mouse studies. Incubation of 
wild‑type hippocampal neurons with NMDA resulted 
in increased locally translated dendritic DSCAM pro‑
tein levels (Alves‑Sampaio et al. 2010). This effect is 
absent in Ts1Cje hippocampal neurons, where basally 
increased DSCAM levels are observed (Alves‑Sampaio 
et al. 2010). Moreover, elevation of DSCAM protein level 
in both wild‑type and Ts1Cje hippocampal neurons was 
abolished by treatment with an NMDA antagonist (APV) 
(Alves‑Sampaio et al. 2010). In turn, DSCAM‑mediated 
mechanisms may be important factors during changes 
in synaptic plasticity, where earlier history of synapse 
activity is an important factor. 
The contribution of NMDA receptors to neuropsy‑
chiatric disorders is well‑known. Ketamine, an NMDA 
antagonist, is capable of producing rapid antidepres‑
sant effects in humans (Banasr et al. 2011). Ketamine 
also produces rapid therapeutic effects for bipolar de‑
pression and patients with suicidal ideation (Banasr et 
al. 2011, Grady et al. 2017) and this is particularly rel‑
evant because Amano et al. (2008) demonstrated in‑
creased DSCAM levels in bipolar patients. While a pos‑
sible connection between DSCAM and bipolar disorder 
was suggested in this study, because of its ethnic under‑
tone further studies are needed to validate the findings. 
The therapeutic target of ketamine is known, being the 
mammalian target of rapamycin (mTOR) (Banasr et al. 
2011). Postmortem studies of depressed patients found 
a potential association between mTOR signaling activity 
and deficits in synaptic proteins (Jernigan et al. 2011). 
The fast antidepressant‑like effect of ketamine was dis‑
played with increased hippocampal and prefrontal corti‑
cal mTOR and brain‑derived neurotrophic factor (BDNF) 
levels (Zhou et al. 2013). The increased synthesis of 
BDNF was proposed as a mechanism to block the NMDA 
receptor (Szewczyk et al. 2012). Furthermore, chronic 
antidepressant treatment resulted in increased BDNF 
levels (Duric and Duman 2013). 
Viewed in the context of learning and memory for‑
mation, (Banasr et al. 2011, Hoeffer and Klann 2010) the 
dendritic presence of mTOR signaling elements is very 
important (Jernigan et al. 2011). The hyperactivation of 
the Akt‑mTOR pathway is a characteristic outcome of DS 
disability (Troca‑Marίn et al. 2012). The Ts1Cje model of 
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DS manifested increased phosphorylation of Akt‑mTOR 
as a result of increased levels of pro‑BDNF and BDNF 
(Troca‑Marίn et al. 2012). It is known that DS individ‑
uals exhibit an age‑related increase in BDNF levels (Do‑
gliotti et al. 2010). Studies on mouse DS models suggest 
that impaired hippocampal synaptic plasticity coupled 
with impaired local translation is an outcome of basal‑
ly saturated NMDA signaling, and loss of synaptic sen‑
sitivity as a result of changes in Glutamate/BDNF (Tro‑
ca‑Marίn et al. 2012). One of the steps in this direction is 
increased local translation of dendritic mRNA e.g. Dscam 
(Alves‑Sampaio et al. 2010, Troca‑Marίn et al. 2012).
Based on Aplysia research, Li et al. (2011) proposed 
Dscam‑ran trans‑synaptic signaling as necessary for the 
occurrence of long‑term synaptic plasticity (LTP). Fur‑
thermore, it is known that during synapse formation lo‑
cally induced synthesis of new proteins and structural 
modifications are generated, which are then important 
factors in the back‑modulation of synaptic plasticity 
(Kossut 2007). According to Belichenko et al. (2004) pre‑
synaptic terminals and dendritic spines are enlarged in 
Ts65Dn mice accompanied by thickening of the post‑syn‑
aptic density of the CA1 region of the hippocampus (Kurt 
et al. 2004). Taking these all into consideration, the im‑
portant factor in DSCAM‑ran trans‑synaptic signaling, is 
its ability for binding the cytoplasmic fragment with the 
PDZ domain binding‑site (Hortsch and Umemori 2009). 
Such interactions between PSD‑95/Dscam have been 
reported in the vertebrate retina (Yamagata and San‑
es 2010). If these interactions were universal, it would 
open a wide range of possibilities for DSCAM‑dependent 
signaling at the level of modulation of glutamate recep‑
tors, in addition to, NMDAR and metabotropic glutamate 
receptors (mGluRs). Fig. 3 depicts the proposed role of 
DSCAM/Dscam, in the cascade of events during synaptic 
plasticity changes (including research in Aplysia). 
Considering the important role of DSCAM in Glu re‑
ceptor modulation, an important question to ask would 
be, what role does it play in GABA signaling? GABA‑ 
γ‑Aminobutyric acid is the main inhibitory neurotrans‑
mitter in the human brain (Sibley et al. 2007). GABA is 
synthesized from L‑glutamate by L‑glutamic acid de‑
carboxylase (GAD) (Sibley et al. 2007). A shift in balance 
between Glu and GABA is a well‑documented factor in 
the pathophysiology of many psychiatric diseases (Pilc 
et al. 2008). GABA acts through three classes of receptors 
(GABAA, B, and C) (Sibley et al. 2007). 
GABAA receptors are present at inhibitory synapses 
both on dendrites, cell bodies, pre‑, post‑ and extra‑syn‑
aptically (Sibley et al. 2007). An important but often for‑
gotten fact is that GABA plays an inhibitory function in 
the adult brain while at the same time being a fast‑excit‑
atory neurotransmitter in the immature brain (Obrietan 
et al. 2002). Furthermore, the existence of a positive 
feedback loop for GABA/BDNF during early develop‑
ment has been proposed (Obrietan et al. 2002). GABA is 
regarded as an important factor in cognitive and mood 
disorders and is proposed as one of the main inhibito‑
ry factors in Ts65Dn mouse plasticity (Costa and Grybko 
2005). In Ts65Dn mice, there is an increased presence of 
Fig. 3. Schematic drawing of DSCAM localization on a glutamate synapse.
Following Li et al. (2009), Dscam is a fi rst‑step safeguard in a whole cascade 
of events during glutamate synapse communication (A). It not only 
stabilizes the pre‑synaptic part to the post‑synaptic but is a guarantor of 
precise timing during this process. When pre‑synaptically Glu is released, 
timed with depolarization, Mg 2+ ions are released and binding of Glu to 
the post‑synaptic part occurs, allowing permeation of Ca 2+ ions (Pochwat 
et al. 2014). NMDA is composed of three main groups of subunits: 
GluN1, GluN2 (GluN2A, GluN2B, GluN2C, GluN2D) and GluN3 (GluN3A, 
GluN3B) (Paoletti et al. 2013). It was documented, that during LTP a larger 
involvement of GluN1/GluN2A in total activity takes part (Paoletti et al. 
2013). In opposition, LTD‑engages mostly GluN1/GluN2B subunits (Paoletti 
et al. 2013). Ca 2+ entry through NMDA receptors, or release by activation of 
metabotropic receptors, activates intracellular signaling pathways: inositol 
triphosphate (IP3), activation of CaMKII and insertion of GluR‑1 AMPA 
receptor into the post‑synaptic membrane. This process involves Dscam, 
as Li et al. (2009) documented its role in AMPA receptor stabilization (B). 
Furthermore, DSCAM protein level is regulated by NMDA‑dependent 
synaptic activity and regulation is lost in trisomic neurons. The whole 
cascade of events is engaged in signaling, from the synapse to the nucleus, 
if gene transcription has to occur (mitogen activated protein kinase (MAPK), 
cAMP‑responsive element binding protein (CREB). CREB activation seems 
to be most important step in this cascade, initiating protein synthesis and 
leading to occurrence of LTP. One of the early genes in the process of 
synaptic plasticity is brain‑derived neurotrophic factor (BDNF). Increased 
BDNF release is connected with activation of AMPA and mTOR pathways. 
These pathways are disrupted in DS persons, as Troca‑Marίn et al. (2012) 
showed increased local translation of BDNF, with greatest AMPA receptor 
delivery and occurrence of an excitatory loop.
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GABA‑ergic interneurons in the hippocampus and cor‑
tex resulting in a GABA‑ergic imbalance (Contestabile 
et al. 2017). Blockade of GABAA receptors in the hippo‑
campus of these mice may reverse LTP impairment and 
cognitive efficiency (Cramer and Galdzicki 2012). Immu‑
nohistochemical study of the dentate gyrus in Ts65Dn 
mice showed a shift of GABA‑ergic synapses to the spine 
necks, which may contribute to impairment of synaptic 
integration (Contestabile et al. 2017). 
Glutamate/GABA‑ergic imbalance was also suggest‑
ed as the cause of cognitive behavioral changes in PTSD, 
DS, depression, and AD (Contestabile et al. 2017, Costa 
and Grybko 2005, Gao et al. 2014, Li et al. 2016, Pilc et 
al. 2008). It is now well known that neural cell adhe‑
sion molecules (NCAMs) influence GABA‑ergic synapse 
specificity (Sassoè‑Pognetto et al. 2011). IgSF9b, a syn‑
aptic adhesion molecule is highly expressed in inhib‑
itory synapses of the hippocampus, cortical neurons, 
and GABA‑ergic interneurons. More importantly, it 
plays a role in major depressive disorder (Shyn et al. 
2011, Woo et al. 2013). According to Woo et al. (2013), 
the down‑regulation of IgSF9b may result in high GA‑
BA‑ergic transmission to pyramidal cells resulting in 
overall inhibition. However, it is astounding that there 
is a lack of research on DSCAM and GABA modulation. 
Table IB summarizes changes observed in the levels of 
DSCAM, Glu, GABA, and modulation of LTP in the dis‑
eases discussed in this review. 
CONCLUSIONS
Over the years, research has shown that upregulation 
of DSCAM is involved in cognitive dysregulation and thus 
is a major cause of mental retardation. However, to date 
only a few studies have documented its involvement in 
mood disorders. Interestingly, DSCAM is regulated by 
the NMDA pathway and is linked to the dysregulation 
of m‑TOR, resulting in intellectual disability. Although 
studies of DSCAM in the context of mood are sparse, the 
association of the Glu pathway with DSCAM indicates 
a fruitful and exciting track for future research, as this 
gene/protein seems to be engaged in regulation of den‑
drite morphology and synaptic plasticity outside of DS.
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